Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$202K Hold
4,200
0.02% 326
2025
Q4
$204K Hold
4,200
0.02% 290
2025
Q3
$198K Hold
4,200
0.03% 295
2025
Q2
$203K Hold
4,200
0.03% 289
2025
Q1
$233K Hold
4,200
0.04% 260
2024
Q4
$203K Hold
4,200
0.03% 269
2024
Q3
$242K Hold
4,200
0.04% 229
2024
Q2
$204K Sell
4,200
-414
-9% -$20K 0.04% 240
2024
Q1
$224K Hold
4,614
0.04% 224
2023
Q4
$229K Hold
4,614
0.04% 216
2023
Q3
$247K Hold
4,614
0.06% 187
2023
Q2
$249K Hold
4,614
0.05% 192
2023
Q1
$251K Sell
4,614
-82
-2% -$3.99K 0.06% 189
2022
Q4
$227K Buy
4,696
+4,282
+1,034% +$188K 0.06% 189
2022
Q3
$16K Hold
414
﹤0.01% 568
2022
Q2
$21K Hold
414
0.01% 532
2022
Q1
$21K Hold
414
0.01% 550
2021
Q4
$21K Buy
+414
New +$20.5K 0.01% 521
2021
Q3
Sell
-505
Closed -$27K 806
2021
Q2
$27K Buy
+505
New +$26.4K 0.01% 465

Other funds holding SNY

CVA Family Office's SNY Position: Q1 2026 in Review

CVA Family Office held its Sanofi (SNY) position steady in Q1 2026 at 4,200 shares worth $202K. The position accounts for 0.02% of the portfolio, ranked #326.

CVA Family Office first reported a position in SNY in Q2 2021 and has held it in 19 quarters since. The position peaked at $251K in Q1 2023. 738 funds tracked by Wall St. Rank hold SNY as of Q1 2026.

  • CVA Family Office held 4,200 shares of Sanofi worth $202K as of Q1 2026.
  • CVA Family Office left its Sanofi share count unchanged in Q1 2026.
  • Sanofi made up 0.02% of CVA Family Office's portfolio in Q1 2026, its #326 holding.
  • CVA Family Office first reported a position in Sanofi in Q2 2021 and has held it in 19 quarters since.
  • CVA Family Office's Sanofi position peaked at $251K in Q1 2023.
  • 738 funds tracked by Wall St. Rank held Sanofi as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.